Esophageal Squamous Cell Carcinoma
Conditions
Interventions
experimental group:PD-L1/TGF-ßRII
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patients who voluntarily participated and signed the informed consent in writing; 2. Patients aged 18-75 years old, regardless of gender; 3. Patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (excluding adenosquamous carcinoma mixed type) confirmed by histopathology; 4. According to recist1.1, patients with at least one measurable lesion; 5. Patients who have not received systemic therapy in the past, or who relapse more than 6 months after the end of (neoadjuvant therapy / radical surgery), including patients with advanced or recurrent non target lesions who progress again after radiotherapy alone. Palliative treatment for local lesions (non target lesions) lasted for more than 4 weeks; 6. The patients with expected survival time >= 3 months; 7. The subjects with ECoG score of 0-1.
Exclusion criteria
Exclusion criteria: 1. Patients who could not tolerate endoscopic biopsy; 2. Patients with anastomotic recurrence after operation; 3. Patients with clear gastrointestinal bleeding concerns (such as local active ulcer lesions, positive stool occult blood); patients with a history of gastrointestinal bleeding within 6 months; patients with a history of gastrointestinal bleeding within 6 months; 4. Patients with known uncontrolled or symptomatic active central nervous system (CNS) metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Countries
China
Contacts
Public ContactYufeng Cheng
Qilu Hospital of Shandong University
Outcome results
None listed